Fabio Petrocca, MD
Oncologist
Existing Patients
Make an appointment by phone
617.414.0940
Make an appointment with MyChart
Book with MyChart
New Patients
If you are a new patient and need an appointment, please contact us at the phone number below.
Learn more about coming to BMC. 617.414.0940Refer a Patient
Refer a patient
Call for assistance with the referral process
617.414.0940
-
Specialties
Hematologic malignancies, lymphomas, leukemias, multiple myeloma
-
Departments
My Contact Information
- 617.414.0940
-
Primary Location
830 Harrison Ave
3rd Floor
Boston, MA 02118
-
Pronouns
He/Him
More About Me
-
Administrative Title
Director, Cellular Therapy Program and Assistant Professor of Medicine, Boston University Chobanian & Avedisian School of Medicine -
Education
University of Rome, Sapienza, Italy, 2004 -
Residency
Oncology, University of Ferrara, Italy, 2004-2008 -
Fellowship
Research Fellowship, Program in Cellular and Molecular Medicine, Harvard Medical School, 2008-2012 -
Board Certifications
Oncology (Italy) -
Special Interests
Hematologic malignancies, lymphomas, leukemias, multiple myeloma -
Languages
Italian
My Publications
-
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. -
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. - BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined. Here, we perform single cell genomic characterization of longitudinal samples from a patient who relapsed after initial CAR T cell treatment with lack of response to retreatment.
- Very little is known about the risk that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection poses to cancer patients, many of whom are immune compromised causing them to be more susceptible to a host of infections. In this case report, we detail the successful treatment of a relapsed and refractory multiple myeloma (MM) patient treated with an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy immediately following clinical recovery from COVID-19.
Affiliations
Boston University is a leading private research institution with two primary campuses in the heart of Boston and programs around the world.
As the principal teaching affiliate of Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center is devoted to training future generations of healthcare professionals. Learn more about Boston University Chobanian & Avedisian School of Medicine.
See my Boston University Chobanian & Avedisian School of Medicine profile
Latest from HealthCity
BMC Aims to Offer Costly, One-Time Cancer Therapy To All
CAR T, a personalized cell therapy, has been a game-changer for certain blood cancers, but its high cost has been a huge barrier to equitable access.

HealthCity is Boston Medical Center's online publication that explores the most pressing issues in healthcare. At HealthCity, we believe that healthcare must transform itself to become more equitable, sustainable, and open source.